Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Iovance Biotherapeutics (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ESMO Asia 2023 | PERLA trial outcomes in global and Asian subgroup populations

Beung Chul Ahn, MD, National Cancer Center, Seoul, South Korea, summarizes the outcomes of the Phase II PERLA trial (NCT04581824), the first global double-randomized study comparing the efficacy of PD-1 inhibitors dostarlimab and pembrolizumab in patients with non-small cell lung cancer (NSCLC). Treatment was administered alongside chemotherapy (CT) and progression-free survival (PFS) measured as the primary endpoint. Subgroup analyses in Asian populations support the hypotheses of this trial, although small sample sizes support the requirement for further studies into dostarlimab and CT treatment. With immunotherapy and CT as the current first-line treatment, further studies combining and comparing this with dostarlimab should be considered. This interview took place at the European Society for Medical Oncology (ESMO) Asia 2023 Congress in Singapore.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.